Prescribing patterns of antiparkinsonian agents in Europe
Identifieur interne : 001A94 ( Main/Exploration ); précédent : 001A93; suivant : 001A95Prescribing patterns of antiparkinsonian agents in Europe
Auteurs : Mário Miguel Rosa [Portugal] ; Joaquim J. Ferreira [Portugal] ; Miguel Coelho [Portugal] ; Rita Freire [Portugal] ; Cristina Sampaio [Portugal]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-06-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (economics), Antiparkinson Agents (supply & distribution), Antiparkinson Agents (therapeutic use), Europe, Europe (epidemiology), Humans, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease treatment, Physician's Practice Patterns (economics), Physician's Practice Patterns (statistics & numerical data), Treatment, antiparkinsonian drugs, health disparities, pharmacoepidemiology, prescribing patterns.
- MESH :
- chemical , economics : Antiparkinson Agents.
- chemical , supply & distribution : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- geographic , epidemiology : Europe.
- drug therapy : Parkinson Disease.
- economics : Physician's Practice Patterns.
- epidemiology : Parkinson Disease.
- statistics & numerical data : Physician's Practice Patterns.
- Humans.
Abstract
In the 1990s, previous knowledge and randomized controlled trials supported the establishment of today's therapeutic recommendations in Parkinson's disease (PD). Scientific evidence allows different options for the treatment of PD. Patterns of use of antiparkinsonian agents (APA) across European countries may thus reflect these options. We wanted to describe patterns of use of APA in Europe and characterize the changes in prescription habits between 2003 and 2007. We investigated APA outpatient sales in 26 European countries where all commercially available APA were studied. Data for molecules and brand names were collected through IMS Health. Treatment per 1000 inhabitants daily (DID) was obtained from the WHO defined daily dose. Prescription pattern changes were evaluated by market share. Prescription patterns varied widely. In most countries, levodopa/dopamine agonists accounted for half of the drug use; whereas in others, anticholinergics, MAO inhibitors and amantadine prevailed. The greatest increase occurred with monoamine oxidase inhibitors and levodopa. There was an increase in dopamine agonists and a decrease in anticholinergics. For a 6.8% dose consume increase, there was a 41.1% sales increase (in euros). We showed an increase in the consumption of APA over 5 years. There was significant heterogeneity in the use of APA in Europe, suggesting differences in drug treatment. Costs of medication increased more than did dose consume, implying an increase in the cost of individual patient treatment. Published evidence does not explain the observed differences in the prescribing of APA. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23038
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F08
- to stream Istex, to step Curation: 000F08
- to stream Istex, to step Checkpoint: 000773
- to stream PubMed, to step Corpus: 001893
- to stream PubMed, to step Curation: 001893
- to stream PubMed, to step Checkpoint: 001692
- to stream Ncbi, to step Merge: 002B09
- to stream Ncbi, to step Curation: 002B09
- to stream Ncbi, to step Checkpoint: 002B09
- to stream Main, to step Merge: 001F30
- to stream PascalFrancis, to step Corpus: 000A71
- to stream PascalFrancis, to step Curation: 002248
- to stream PascalFrancis, to step Checkpoint: 000895
- to stream Main, to step Merge: 002482
- to stream Main, to step Curation: 001A94
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prescribing patterns of antiparkinsonian agents in Europe</title><author><name sortKey="Rosa, Mario Miguel" sort="Rosa, Mario Miguel" uniqKey="Rosa M" first="Mário Miguel" last="Rosa">Mário Miguel Rosa</name></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name></author><author><name sortKey="Freire, Rita" sort="Freire, Rita" uniqKey="Freire R" first="Rita" last="Freire">Rita Freire</name></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CCF21BAA386010E363975DC056C25BD15DEA69F1</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23038</idno><idno type="url">https://api.istex.fr/document/CCF21BAA386010E363975DC056C25BD15DEA69F1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F08</idno><idno type="wicri:Area/Istex/Curation">000F08</idno><idno type="wicri:Area/Istex/Checkpoint">000773</idno><idno type="wicri:doubleKey">0885-3185:2010:Rosa M:prescribing:patterns:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20222132</idno><idno type="wicri:Area/PubMed/Corpus">001893</idno><idno type="wicri:Area/PubMed/Curation">001893</idno><idno type="wicri:Area/PubMed/Checkpoint">001692</idno><idno type="wicri:Area/Ncbi/Merge">002B09</idno><idno type="wicri:Area/Ncbi/Curation">002B09</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B09</idno><idno type="wicri:Area/Main/Merge">001F30</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0314987</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A71</idno><idno type="wicri:Area/PascalFrancis/Curation">002248</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000895</idno><idno type="wicri:doubleKey">0885-3185:2010:Rosa M:prescribing:patterns:of</idno><idno type="wicri:Area/Main/Merge">002482</idno><idno type="wicri:Area/Main/Curation">001A94</idno><idno type="wicri:Area/Main/Exploration">001A94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prescribing patterns of antiparkinsonian agents in Europe</title><author><name sortKey="Rosa, Mario Miguel" sort="Rosa, Mario Miguel" uniqKey="Rosa M" first="Mário Miguel" last="Rosa">Mário Miguel Rosa</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Freire, Rita" sort="Freire, Rita" uniqKey="Freire R" first="Rita" last="Freire">Rita Freire</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15">2010-06-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1053">1053</biblScope><biblScope unit="page" to="1060">1060</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CCF21BAA386010E363975DC056C25BD15DEA69F1</idno><idno type="DOI">10.1002/mds.23038</idno><idno type="ArticleID">MDS23038</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (economics)</term><term>Antiparkinson Agents (supply & distribution)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Europe</term><term>Europe (epidemiology)</term><term>Humans</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson disease</term><term>Parkinson's disease treatment</term><term>Physician's Practice Patterns (economics)</term><term>Physician's Practice Patterns (statistics & numerical data)</term><term>Treatment</term><term>antiparkinsonian drugs</term><term>health disparities</term><term>pharmacoepidemiology</term><term>prescribing patterns</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Physician's Practice Patterns</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Physician's Practice Patterns</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Europe</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the 1990s, previous knowledge and randomized controlled trials supported the establishment of today's therapeutic recommendations in Parkinson's disease (PD). Scientific evidence allows different options for the treatment of PD. Patterns of use of antiparkinsonian agents (APA) across European countries may thus reflect these options. We wanted to describe patterns of use of APA in Europe and characterize the changes in prescription habits between 2003 and 2007. We investigated APA outpatient sales in 26 European countries where all commercially available APA were studied. Data for molecules and brand names were collected through IMS Health. Treatment per 1000 inhabitants daily (DID) was obtained from the WHO defined daily dose. Prescription pattern changes were evaluated by market share. Prescription patterns varied widely. In most countries, levodopa/dopamine agonists accounted for half of the drug use; whereas in others, anticholinergics, MAO inhibitors and amantadine prevailed. The greatest increase occurred with monoamine oxidase inhibitors and levodopa. There was an increase in dopamine agonists and a decrease in anticholinergics. For a 6.8% dose consume increase, there was a 41.1% sales increase (in euros). We showed an increase in the consumption of APA over 5 years. There was significant heterogeneity in the use of APA in Europe, suggesting differences in drug treatment. Costs of medication increased more than did dose consume, implying an increase in the cost of individual patient treatment. Published evidence does not explain the observed differences in the prescribing of APA. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Portugal</li></country></list><tree><country name="Portugal"><noRegion><name sortKey="Rosa, Mario Miguel" sort="Rosa, Mario Miguel" uniqKey="Rosa M" first="Mário Miguel" last="Rosa">Mário Miguel Rosa</name></noRegion><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><name sortKey="Freire, Rita" sort="Freire, Rita" uniqKey="Freire R" first="Rita" last="Freire">Rita Freire</name><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CCF21BAA386010E363975DC056C25BD15DEA69F1
|texte= Prescribing patterns of antiparkinsonian agents in Europe
}}
| This area was generated with Dilib version V0.6.23. |  |